Prof. Yesim Gkmen-Polar

Emory University School of Medicine, USA

Email: [email protected]

Qualifications

1990 Ph.D., Bogazici University, Molecular Biology

1988 M.Sc., Bogazici University, Molecular Biology

1983 B.Sc., Bogazici University, Biology

Publications (selected)

1. Canaslan, K., Nia, F. M., Baez, M., et al. (2026). Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy (vol 75, 110, 2026). Cancer Immunology Immunotherapy, 75(6), Article 164.
2. Slusher, G. A., Gu, Y., Badve, S. S., et al. (2026). Distinct metabolic adaptations to resistance to CDK4/6 inhibitors in ER plus breast cancer identified using microfluidic mass spectrometry platform. Cancer Research, 86(7, Suppl. S), Abstract 1895.
3. Canaslan, K., Nia, F. M., Baez, M., et al. (2026). Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy. Cancer Immunology Immunotherapy, 75(4), Article 110.
4. Mammadova, A., Gu, Y., Ruan, L., et al. (2026). Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer. Biomolecules, 16(1), Article 93.
5. Wilde, C., Anwar, S., Yau, Y. T., et al. (2025). A Thymus-Independent Artificial Organoid System Supports Complete Thymopoiesis from Rhesus Macaque-Derived Hematopoietic Stem and Progenitor Cells. Biomedicines, 13(11), Article 2692.
6. Huang, J., Yuan, C. Y., Jiang, J. H., et al. (2025). Bridging cell morphological behaviors and molecular dynamics in multi-modal spatial omics with MorphLink. Nature Communications, 16(1), Article 5878.
7. Larijani, F. A., Behrouzi, P., Galassi, L., et al. (2025). Leveraging AI predictive models to develop thymic tumor-specific peptides mimicking COL17A1 alterations. Journal of Clinical Oncology, 43(16_suppl), Abstract e20138.
8. Badve, S. S., Liu, S. H., Basu, M., et al. (2025). Spatial transcriptomic analysis of breast cancer patients with early and late progression of disease after endocrine and CDK4/6 treatments: deconvoluting the tumor microenvironment. Cancer Research, 85(8, Suppl. 1), Abstract 416.
9. Allam, M., Coskun, A., Hu, T., et al. (2024). Metabolic alterations in Estrogen Receptorpositive breast cancer contributing to CDK4/6 resistance. Cancer Research, 84(9, Suppl. S), Abstract PO5-23-09.
10. Badve, S., Hu, J., Zhang, Y., et al. (2024). Ectopic expression of lineage-specific transcription factors in Breast Cancer. Cancer Research, 84(9, Suppl. S), Abstract PO4-16-03.
11. Ghose, S., Davis, C., Cho, S., et al. (2024). Spatial heterogeneity of tumor boundary in mammograms is prognostic of recurrence in triple negative breast cancer (TNBC). Cancer Research, 84(6, Suppl. S), Abstract 4925.
12. Gokmen-Polar, Y., Gu, Y., Ruan, L., et al. (2024). CDK4/6 therapy-induced senescence as a resistance mechanism-MiDAS touch. Cancer Research, 84(6, Suppl. S), Abstract 5861.
13. Keskinkilic, M., Gökmen-Polar, Y., & Badve, S. S. (2024). Triple Negative Breast Cancers: An Obsolete Entity? Clinical Breast Cancer, 24(1), Article 006.
14. Badve, S. S. S., & Gokmen-Polar, Y. (2023). Targeting the Tumor-Tumor Microenvironment Crosstalk. Expert Opinion on Therapeutic Targets.
15. Ghose, S., Cho, S. H., Ginty, F., et al. (2023). Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model. Cancers, 15(7), Article 1922.
16. Mudge, Z. B., Kovacs, K., Kemp, M. L., et al. (2023). Genome-scale metabolic modeling suggests novel molecular targets in ER-positive breast cancer. Cancer Research, 83(7, Suppl. S), Abstract 3162.
17. Aldrich, J., Hu, T., Switchenko, J., et al. (2023). Predicting the likelihood of response in PDL-1 positive metastatic triple negative breast cancer treated with an immune checkpoint inhibitor. Cancer Research, 83(5, Suppl. S), Abstract P1-04-14.
18. Soumya, G., Gokmen-Polar, Y., Cho, S., et al. (2023). Recurrence Prediction in Ductal Carcinoma In Situ (DCIS) Patients from Tissue Microarrays (TMAs). Cancer Research, 83(5, Suppl. S), Abstract P6-04-10.
19. Gökmen-Polar, Y., Gu, Y., Polar, A., et al. (2023). The Role of ESRP1 in the Regulation of PHGDH in Estrogen Receptor-Positive Breast Cancer. Laboratory Investigation, 103(3), Article 100002.
20. Badve, S. S., & Gökmen-Polar, Y. (2023). A predictor of response in HER21 breast cancer-at last!. JNCI-Journal of the National Cancer Institute, 115(3), 242–245.

Profile Details
https://winshipcancer.emory.edu/profiles/polar-yesim.php
https://scholar.google.com/citations?user=5HwhwAQAAAAJ&hl=en
https://www.researchgate.net/profile/Yesim-Gokmen-Polar

WOS ResearcherID: AAX-4001-2021